Watson J E, Karmazyn M
Department of Pharmacology and Toxicology, University of Western Ontario, London, Canada.
Circ Res. 1991 Oct;69(4):1114-31. doi: 10.1161/01.res.69.4.1114.
An extensive investigation of the cardiac actions of phorbol esters and the potential role of the Na(+)-H+ exchanger in those actions was carried out using isolated rat hearts. Sixty minutes of perfusion with 10(-9) M phorbol 12-myristate 13-acetate (PMA) or 10(-8) M phorbol 12,13-dibutyrate (PDBu) produced marked cardiac dysfunction associated with depressed contractility, coronary constriction, and elevated resting tension, the latter being particularly evident with PMA. These effects were also associated with disturbances in tissue levels of energy metabolites manifested primarily by a reduction in ATP and an elevation in lactate. Furthermore, both phorbols produced a sustained stimulation of the release of 6-ketoprostaglandin F1 alpha (6-keto PGF1 alpha), the hydrolysis product of prostacyclin (prostaglandin I2). Amiloride, an inhibitor of the Na(+)-H+ exchanger, significantly attenuated the loss in contractility and elevation in coronary pressure as well as the stimulated release of 6-keto PGF1 alpha but was without effect on elevations in resting tension or on changes in energy metabolites. Increasing concentrations of PMA or PDBu 10-fold resulted in a much more rapid and severe (greater than 80% loss in contractile function after 30 minutes) effect that was nonetheless qualitatively identical to that seen with the lower concentrations of phorbol. However, the effects were not prevented by amiloride. Surprisingly, 4 alpha-phorbol 12,13-didecanoate (alpha-PDD, 10(-6) M), which does not activate protein kinase C, was found to be a potent inhibitor of cardiac function (greater than 80% loss in contractility and 50% increase in resting tension) after 30 minutes of perfusion, although these effects were not associated with changes in levels of energy metabolites or with elevations in coronary pressure. Similarly, none of the actions of this compound were attenuated by amiloride. In contrast to the sustained effects of other phorbols on 6-keto PGF1 alpha release, the effect of alpha-PDD was transient (less than 10 minutes). In all hearts studied, the marked depression in contractile function caused by all phorbol esters occurred in the absence of any ultrastructural changes. 4 alpha-Phorbol (10(-6) M), which does not activate protein kinase C, was without effect on any parameter studied. Our results demonstrate very complex effects of phorbol esters on numerous parameters of cardiac function, including an amiloride-sensitive component that occurs at low concentrations. The latter observation suggests the involvement of Na(+)-H+ exchange activation, possibly occurring as a consequence of protein kinase C stimulation, in mediation of the effects of phorbol esters at low concentrations.(ABSTRACT TRUNCATED AT 400 WORDS)
利用离体大鼠心脏,对佛波酯的心脏作用以及钠氢交换体在这些作用中的潜在作用进行了广泛研究。用10⁻⁹ M佛波醇12 - 肉豆蔻酸酯13 - 乙酸酯(PMA)或10⁻⁸ M佛波醇12,13 - 二丁酸酯(PDBu)灌注60分钟,会导致明显的心脏功能障碍,表现为收缩力降低、冠状动脉收缩和静息张力升高,后者在PMA作用下尤为明显。这些效应还与能量代谢产物组织水平的紊乱有关,主要表现为ATP减少和乳酸升高。此外,两种佛波酯均能持续刺激前列环素(前列腺素I2)的水解产物6 - 酮前列腺素F1α(6 - 酮PGF1α)的释放。钠氢交换体抑制剂阿米洛利可显著减轻收缩力的丧失和冠状动脉压力的升高,以及6 - 酮PGF1α的刺激释放,但对静息张力升高或能量代谢产物的变化无影响。将PMA或PDBu的浓度增加10倍会导致更快速、更严重的效应(30分钟后收缩功能丧失超过80%),但其性质与较低浓度佛波酯所见效应相同。然而,阿米洛利并不能阻止这些效应。令人惊讶的是,不激活蛋白激酶C的4α - 佛波醇12,13 - 十二烷酸酯(α - PDD,10⁻⁶ M)在灌注30分钟后被发现是心脏功能的有效抑制剂(收缩力丧失超过80%,静息张力增加50%),尽管这些效应与能量代谢产物水平的变化或冠状动脉压力升高无关。同样,该化合物的任何作用都未被阿米洛利减弱。与其他佛波酯对6 - 酮PGF1α释放的持续效应相反,α - PDD的效应是短暂的(少于10分钟)。在所有研究的心脏中,所有佛波酯引起的收缩功能明显降低均未伴有任何超微结构变化。不激活蛋白激酶C的4α - 佛波醇(10⁻⁶ M)对所研究的任何参数均无影响。我们的结果表明,佛波酯对心脏功能的众多参数具有非常复杂的影响,包括低浓度时出现的阿米洛利敏感成分。后一观察结果表明,钠氢交换体激活可能参与了低浓度佛波酯作用的介导,这可能是蛋白激酶C刺激的结果。(摘要截断于400字)